SynthesisJournal of medical virology2025
The Neuroimmunome of Hepatitis Patients Associates With Disease Severity.
Synthesis in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- The Neuroimmunome of Hepatitis Patients Associates With Disease Severity.Journal of medical virology · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Hepatitis is a systemic disease marked by neuroimmune dysregulation beyond hepatic inflammation. Using a systems biology approach, we conducted transcriptomic meta-analyses across in vitro models, liver tissues, and PBMCs from hepatitis virus-infected patients to identify neuroimmune signatures. We found a robust neuroimmunome signature, with neuroimmune-related genes showing consistent differential expression across datasets. Functional enrichment revealed disruptions in neurotransmission (including synaptic, glutamatergic, noradrenergic and neuregulin pathways) and immune signaling (such as cytokines, interleukin-1 response, T cell receptor, and trans-synaptic signaling). Linear discriminant analysis (LDA) demonstrated that neuroimmune genes can predict disease severity. Several of these genes were also altered in hepatocellular carcinoma (HCC) samples from The Cancer Genome Atlas Program (TCGA), implicating them in oncogenic transformation. Ligand-receptor analysis revealed dysregulated neuroimmune interactions in liver tissue, notably involving DBH-ADRA1A/B/D, ADRA2A/B/C, ADRB1/2/3, IL33-IL1RL1, and NRG1-ERBB4. Critically, we observed an inverse correlation between neuroimmune gene expression and inflammation markers in advanced HCC, suggesting that neuroimmune suppression may facilitate immune evasion. These findings highlight the neuroimmunome as a potential biomarker and therapeutic target in hepatitis and its complications, reinforcing the role of neuroimmune crosstalk in liver disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.